Background Self-injurious behaviour is a debilitating characteristic that is commonly expressed in people with autism and other neurodevelopmental disorders, but the neurobiological basis of this maladaptive behaviour is not understood. Abnormal dopaminergic and glutamatergic neurotransmission has been implicated, especially in relation to basal ganglia and mesocorticolimbic circuits. As neurotensin is an important modulator of dopamine and glutamate in these circuits, we investigated its potential role in vulnerability for self-injury, using the pemoline model in rats. Methods Male Long-Evans rats were injected once daily with the psychostimulant pemoline or peanut oil vehicle on each of five consecutive days. Self-injury was quantified by measuring the area of injuries for each rat on each day of the experiment. Each brain was harvested on the sixth day, and the striatum and ventral tegmentum were dissected. Neurotensin-like immunoreactivity was quantified by radioimmunoassay from the dissected brain regions of some of the rats. Membrane and intracellular neurotensin receptor NTS 1 were assayed from the striata of the remaining pemoline-treated or vehicle-treated rats by Western blot. In an additional experiment, male Long-Evans rats were treated with daily injections of vehicle or pemoline, and the NTS 1 neurotensin receptor agonist PD149163 or the NTS 1 receptor antagonist SR48692 (or respective vehicle solutions)
Self-injurious behaviour (SIB) is a highly prevalent characteristic that is expressed by people with a variety of neurodevelopmental disorders (Rojahn and Esbensen 2002) . This includes children with autism spectrum disorder (Matson et al. 1996) , LeschNyhan, Prader-Willi, Rett, and Fragile X syndromes (Lesch and Nyhan 1964; Schretlen et al. 2005; Symons et al. 1999) , and unspecified intellectual disabilities (McClintock et al. 2003) . Children who self-injure are at risk for varying degrees of tissue injury that range from mild to severe (Baghdadli et al. 2003) . However, even in the case of mild SIB, there are serious detrimental impacts upon family and caretakers (Bromley and Emerson 1995; Findling 2005) . In addition, SIB interferes with educational and socialising activities (Findling 2005; Matson and Nebel-Schwalm 2007) , and imposes a severe economic burden (NIH Consensus Statement 1989) .
Although progress has been made in reducing problem behaviours like self-injury through environmental interventions and behaviour therapy (Hanley et al. 2003) , the neurobiological basis of these behaviours is still poorly understood. Most research has focused upon basal ganglia and mesocorticolimbic circuitry, and abnormalities have been reported in striatal dopaminergic and glutamatergic functioning. For example, studies of children with Lesch-Nyhan syndrome reveal reduced caudate volume (Harris et al. 1998 ) with reduced dopamine content, reduced dopamine transporter density and reduced striatal fluorodopa uptake (Visser et al. 2000) .
Studies in animal models of SIB also reveal important roles of striatal dopaminergic and glutamatergic signalling (for review, refer to Devine (2012a) ). For example, in the 6-hydroxydopamine lesion model, neonatal destruction of dopaminergic neurons, followed in adulthood by treatment with dopamine agonists, produces a profound expression of self-biting in rats (Breese et al. 2005) . In intact rats, SIB can be induced by repeated treatment with the indirect dopamine agonist pemoline (for review, refer to Devine 2012b), and these effects are blocked by administration of the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 (King et al. 1995; Muehlmann and Devine 2008) , suggesting that sensitisation to repeated stimulant administration contributes to the aetiology of pemoline-induced SIB and that glutamate transmission is critical to this sensitisation (Muehlmann & Devine 2008) .
The peptide neurotensin is an important modulator of dopaminergic and glutamatergic function in the nigrostriatal and mesocorticolimbic system (for reviews, refer to Ferraro et al. (2008) and Vincent et al. (1999) ), and has been linked to neurodevelopmental disorders that frequently present with self-injury (Boules et al., 2014; Griebel & Holsboer, 2012) . Neurotensin strongly co-localises with dopaminergic neurons (Manberg et al. 1982) , and its receptors are expressed on both the dopaminergic neurons themselves and on their postsynaptic targets (Goedert et al. 1984) . Neurotensin receptors are also located on glutamatergic terminals of corticostriatal neurons (Goedert, Pittaway, & Emson 1984) . Overall, neurotensin binds to at least three different types of receptors. NTS 1 and NTS 2 are G-protein-coupled receptors, and NTSR3 is a single transmembrane presenilin receptor (for review, refer to Vincent, Mazella, & Kitabgi (1999) ). However, the NTS 1 receptor is the only one that is transcribed at high levels in the substantia nigra (SN) and ventral tegmental area (VTA) (Brouard et al. 1992; Nicot et al. 1995) , and the protein is expressed both in the cell body region and the striatum (Nicot et al. 1994) . Accordingly, we investigated the potential that neurotensin actions on NTS 1 receptors contribute to the aetiology of SIB in the pemoline model. We compared neurotensin peptide levels and NTS 1 receptor levels in brain, and we evaluated the effects of a NTS 1 receptor agonist and antagonist on pemoline-induced SIB. For more information on the validity, limitations, and translational value of the pemoline model of SIB, please refer to Devine (2012a Devine ( , 2012b and Devine and Symons (2013) .
Methods
Experiment 1: neurotensin-like immunoreactivity in vehicle-treated and pemoline-treated rats
Animals
Twenty male LE rats weighing 200-225 g upon delivery (Charles River Laboratories, Raleigh, NC) were housed in a climate controlled vivarium with a 12/12-h light/dark schedule (lights on at 7:00 AM). Standard laboratory rat chow (Lab Diet 5001) and tap water were available ad libitum. The rats were pairhoused in standard polycarbonate cages (43 cm × 21.5 cm × 25.5 cm) during 6 days of acclimation to the housing facility. All of the experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, and were preapproved by the Institutional Animal Care and Use Committee at the University of Florida.
Stress responsiveness screening
We have previously reported that individual differences in vulnerability for pemoline-induced SIB can be predicted on the basis of individual differences in innate locomotor responsiveness to the mild stress of a novel environment (Muehlmann et al. 2011) . Therefore, we prescreened the rats and counterbalanced the assignments of the stressresponsive/resilient rats to the pemoline-treated and vehicle-treated groups, following the same screening procedures as in our previous experiment. Briefly, after acclimation to the housing conditions, the rats were tested in the novel environment of a circular corridor (a small plastic cylinder placed inside a larger plastic cylinder, forming a path that was 7 cm wide, with a 44-cm outer diameter). Both cylinders were washed with 4% bleach, and standard bedding was placed on the floor of the circular corridor. Dim illumination was provided by small lamps placed beside each circular corridor. Each rat was individually placed into a circular corridor apparatus between 1 and 2 h after lights on (i.e. between 8 and 9 AM). Overhead video cameras were used to record locomotor behaviour. Locomotion was scored for 60 min from the video recordings by a trained observer who quantified crossings between quadrants of the corridor. One count was recorded each time the rat crossed the complete length of a quadrant.
Drug
The indirect dopamine agonist pemoline (2-amino-5-phenyl-1,3-oxazol-4-one; Everett 1976) was purchased from Spectrum Chemicals, New Brunswick, New Jersey, and was suspended at a concentration of 50 mg/ml in peanut oil.
Drug treatment
Starting on the day after stress responsiveness screening, each rat was weighed and injected with peanut oil vehicle (n = 10) or pemoline (n = 10) at 150 mg/kg (s.c.) each morning for five consecutive days. The injections were administered at the nape of the neck and either flank on a rotating basis.
Assay of self-injury
The rats were visually inspected each time they were injected, and again on the morning of the last day of the experiment (24 h after the final injection of pemoline or vehicle), and the inspections were videorecorded. During these inspections, each rat was held in front of a video camera, and the head, forepaws, hindpaws, ventrum, and tail were displayed. The presence or absence of tissue injury (denuded skin, erythema, oedema, or open lesion) was noted for each rat. Still images of the injured tissue were taken from the video-recordings, and MCID software (Imaging Research Inc., St. Catharines, ON, Canada) was used to draw outlines around the injured tissue, and to calculate the area of each injury in mm 2 .
In all our experiments, any rat that exhibits an open lesion is immediately removed from the experiment and euthanised. This did not occur for any of the rats treated with the low dose of pemoline that was used in these studies.
Each rat was rapidly decapitated 24 h after the last injection; the brain was immediately removed, and the striatum (caudate and nucleus accumbens) and ventral tegmentum (including SN and VTA) were dissected, weighed, frozen on dry ice, and stored at À80°C until processed.
Neurotensin radioimmunoassay
We were interested in assaying neurotensin levels in cell body regions (i.e. ventral tegmentum) and axon terminal regions (i.e. striatum). The neurotensin radioimmunoassay (RIA) was purchased from Phoenix Pharmaceuticals, Inc. (Burlingame, CA) and performed according to their protocol. The dissected brain regions were homogenised by sonication in 10 mM Tris at a ratio of 5 ml buffer per gram of tissue, and the samples were then centrifuged at 12 000×g for 20 min at 4°C.
Supernatants were divided between Bradford protein assay and the neurotensin RIA. For the RIA samples, equal parts of supernatant and buffer A were mixed and centrifuged at 3500 RPM for 15 min at 4°C. These supernatants were then added to equilibrated C-18 Sep-Columns (Phoenix Pharmaceuticals). After washing each column with buffer A twice, neurotensin peptide was eluted off the column with buffer B. The eluant was collected into tubes, which were covered with parafilm with holes poked into it, and frozen in lypholiser jars at À80°C. The samples were dried down in a centrifugal concentrator for 10-12 h, and were then reconstituted in RIA buffer. Rabbit anti-neurotensin primary antibody (raised against synthetic neurotensin) was added to each tube, vortexed, and incubated at 4°C for 21 h. Next,
125
I-neurotensin (with 10 000 cpm/100 μl) was added to each tube, vortexed, and incubated at 4°C for 22 h. Goat antirabbit IgG secondary antibody and normal rabbit serum were then added to each tube, vortexed, and left to incubate at room temperature for 90 min. Radioimmunoassay buffer was then added to each tube, and all the tubes were centrifuged at 3000 RPM for 20 min at 4°C. The supernatants were then aspirated off, and the tubes were read in a gamma counter. The amount of neurotensin in each sample was then extrapolated from a standard curve, which plotted the ratio of bound 125 I-neurotensin in the presence of unlabeled neurotensin (10-1280 pg/ml) or in the absence (0 pg/ml) of neurotensin. These values were then corrected for the amount of protein used for the extraction. In this experiment, two tegmental samples were lost due to methodological error.
Experiment 2: NTS 1 receptor protein in vehicle-treated and pemoline-treated rats
Ten additional male Long-Evans rats (pemoline n = 6, vehicle n = 4) were housed, screened for stress responsiveness, assigned to counterbalanced groups, injected daily with pemoline or vehicle, and examined for evidence of self-injury as in experiment 1. Striata were dissected from the brains of these rats, frozen at À80°C, and used for NTS 1 receptor protein analyses. The methods for protein cross-linking and western blot analyses were adapted from Nelson et al. (2009) . Striatal samples were incubated with protein cross-linking reagent bis(sulfosuccinimidyl) suberate (BS3) at 2 μM in artificial extracellular fluid for 30 min at 4°C with gentle agitation. Chemical cross-linking of proteins in intact cells allows for analysis of surface expressed proteins (which form high molecular weight aggregates when cross-linked, as opposed to the intracellular proteins that are not accessible to the cross-linking reagent). Cross-linking was terminated by quenching the reactions with 500 μl of 300 μM glycine for 10 min at 4°C. Tubes containing the cross-linking reactions were centrifuged at 20 800×g for 2 min at 4°C. Supernatants were discarded, and the protein pellets were sonicated in 25 μl of ice-cold lysis buffer containing protease and phosphatase inhibitors. The tubes were again centrifuged at 20 800×g for 2 min at 4°C. Supernatants were separated, and the total protein content was assayed for each sample using the Lowry method (Total Protein Kit, Sigma). Equal amounts of protein samples were loaded on to 3-8% Tris acetate gels and run under reduced conditions. The proteins were then transferred onto polyvinylidene fluoride membranes. The membranes were incubated with polyclonal rabbit anti-NTS 1 (1:500; Abcam) primary antibody at 4°C, and were then exposed to secondary antibody (horseradish peroxidase-linked anti-rabbit IgG, 1:5000; Cell Signalling) for 1 h at room temperature. Stripped membranes were re-probed with beta-actin primary antibody (rabbit polyclonal, 1:2000; Cell Signalling) and secondary antibody. Membrane-bound and intracellular NTS 1 receptor proteins were detected from high and lower molecular weight bands using the chemiluminescence method, and analysed by densitometry using MCID Image Analysis software. Protein expression levels for NTS 1 receptor were normalised to beta-actin protein levels.
Statistical analyses (experiments 1 and 2)
Between-group differences in area of injured tissue were evaluated using RM-ANOVA. Differences in neurotensin-like immunoreactivity (NTLI) and NTS 1 protein expression in pemoline-treated and vehicle-treated rats were compared using unpaired ttests. Between-group differences in all dependent measures were treated as statistically reliable when the P values were less than 0.05. 
Drug treatments
After acclimation, stress responsiveness screening, and counterbalanced group assignments (refer to experiment 1), each rat was weighed and injected with either peanut oil vehicle or pemoline (150 mg/kg s.c.) at approximately 8:00 AM on each of five consecutive days. These injections were administered at the nape of the neck and either flank on a rotating basis. The rats were also injected twice daily with either saline (control for PD149163), or PD149163 (0.01 mg/kg i. p.), or 0.1% Tween 80 (control for SR48692) or SR48692 (1.0 mg/kg s.c.). These injections were administered at approximately 8:00 AM, (immediately after the pemoline injection) and approximately 6:00 PM and also rotated between the nape of the neck and either flank. The doses of PD149163 and SR48692 were based on our previous studies and prior small dose-response analyses. The drug and vehicle groups are summarised in Table 1 .
Assays of self-injury
The inspections of the rats and the calculations of the areas of injured tissue were conducted in the same manner as in experiment 1. In addition, video cameras with night vision capability were focused on the cages of the rats (one camera per cage), and 5-min time samples were recorded once every 3 h throughout the entire day/night cycle. The duration of self-injurious oral contact was quantified during each recorded interval by a trained observer. Self-injurious oral contact was defined as all oral contact that stayed fixed on any one body part for longer than 2 s. This was differentiated from grooming, which is oral contact with any part of the body that continues to move from site to site on the body (e.g. oral contact with the forepaws, that then moves up each forelimb and continues to the ventrum, and the contact is not sustained at any spot on the body for longer than 2 s). The duration (in seconds) of oral contact behaviour was summed over the entire day (i.e. from the eight video samples) and divided by the total number of seconds recorded (2400 s).
Statistical analyses (experiment 3)
Between-group differences in the area of injured tissue and duration of self-injurious oral contact were each evaluated using RM-ANOVA. Between-group differences in all dependent measures were treated as statistically reliable when the P values were less than 0.05.
Results

Experiment 1
The rats that were treated with five daily injections of pemoline at 150 mg/kg/day exhibited significant selfinjury (Fig. 1a) . There were significant main effects of drug (F (1,180) = 36.17, P < 0.01) and time (F (10,180) = 21.60, P < 0.01) and a significant drug × time interaction (F (10,180) = 17.57, P < 0.01). Significantly higher concentrations of neurotensin were found in the striata of pemoline-treated rats as 1001 compared with the vehicle-treated controls ( Fig. 1b; t(18) = 2.629, P < 0.05). There were no significant between-group differences in neurotensin levels in the tegmenta of the pemoline-treated and vehicle-treated rats ( Fig. 1c; t(16) = 0.747, P > 0.05).
Experiment 2
In the second experiment, once again, the rats that were treated with five daily injections of pemoline at 150 mg/kg/day exhibited significant self-injury (Fig. 2a) . There were significant main effects of drug (F (1,80) = 10.26, P < 0.05) and time (F (10,80) = 4.93, P < 0.01) and a significant drug × time interaction (F (10,80) = 4.93, P < 0.01). There was a significant upregulation of NTS 1 receptor in both surface ( Fig. 2b ; t(8) = 3.071, P < 0.05) and intracellular ( Fig. 2c ; t(8) = 2.602, P < 0.05) protein expressions in pemoline-treated rats compared with vehicletreated controls.
Experiment 3
Rats treated with pemoline plus the NTS 1 receptor agonist PD149163 exhibited significantly greater area of injured tissue (Fig. 3a) and spent significantly more of their time engaging in self-injurious oral contact than did the pemoline-treated controls. For the area of injured tissue measure, a RM-ANOVA revealed a significant effect of time (F (10,220) = 6.124, P < 0.0001) and a significant drug × time interaction (F (30,220) = 2.280, P < 0.001), as pemoline + PD149163-treated rats began to exhibit pemoline-induced self-injury earlier and consistently showed greater injury size throughout the experiment. For the duration of self-injurious oral contact measure, significant effects of drug (F (3, 88) = 23.71, P < 0.0001), time (F (4,88) = 16.47, P < 0.0001) and drug × time interaction (F (12,88) = 6.312, P < 0.0001) were found. Pemoline + PD149163-treated rats were the first to exhibit considerable amounts of selfinjurious oral contact, and their rates of oral contact remained elevated compared those of the pemoline + vehicle-treated rats on days 2-4. The durations of self-injurious oral contact did not differ between these groups on day 5. Conversely, the rats treated with pemoline plus the NTS 1 receptor antagonist SR48692 exhibited significantly smaller areas of injured tissue (Fig. 4a) and spent significantly less time engaged in self- Figure 1 Pemoline-induced self-injury and neurotensin concentrations in striatum and tegmentum. (a) Five daily pemoline injections produced self-induced injury that peaked on day 4 and continued until the end of the experiment on day 6. Values are expressed as group means ± SEM. (b) Neurotensin levels within the striatum were significantly elevated after the five daily pemoline injections, but (c) were not significantly changed in the tegmentum, as compared with neurotensin levels of vehicle-treated rats. Values are expressed as group means + SEM. injurious oral contact (Fig. 4b) , in comparison with measures in the pemoline-treated controls. For the area of injured tissue measure, the RM-ANOVA revealed significant main effects of drug (F (3, 290) = 6.536; P < 0.01) and time (F (10,290) = 11.26, P < 0.0001) and a significant drug × time interaction effect (F (30,290) = 4.875, P < 0.0001). For the self-injurious oral contact measure, an analysis using RM-ANOVA also found significant main effects of drug (F (3, 116) = 30.54, P < 0.0001) and time (F (4,116) = 26.87, P < 0.0001), as well as a significant drug × time interaction effect (F (12,116) = 9.770, P < 0.0001).
Discussion
In this study, we found that repeated pemoline administration increases NTLI in dopaminergic axon terminal regions of the striatum while it induces substantial SIB in rats. Our analysis of NTLI included both dorsal and ventral striatal regions, because both regions of the striatum have been implicated in SIB and other stereotyped behaviours. Future studies will examine whether this increase is found in one or both of these regions. In the striatal terminal regions, we also found that the expression of the NTS 1 receptor protein was increased in pemolinetreated rats. We found elevations in both intracellular and surface expressions of the NTS 1 protein, although the surface/intracellular ratio was unchanged (data not shown).
To our knowledge, this is the first assessment of NTS 1 expression and cellular distribution following subchronic psychostimulant administration, but the effects of pemoline on striatal NTLI resemble effects that have been reported for other psychostimulants. Cocaine and methamphetamine each significantly increase NTLI in the caudate, nucleus accumbens, and tegmentum (Hanson et al. 1992) . Interestingly, these cocaine-induced and methamphetamineinduced increases in NTLI were blocked by pretreatment with the NMDA receptor antagonist MK-801, a pretreatment that also blocks pemolineinduced SIB (King, Au, & Poland 1995; Muehlmann & Devine 2008) .
The striatal NTLI data reveal that repeated pemoline treatment increased neuronal content of neurotensin. However, it does not reveal whether release was actually downregulated, or if the kinetics of the system were upregulated overall, with a more prominent impact on neurotensin biosynthesis. The NTS 1 receptor expression differences are much clearer, and suggest a significant upregulation, most importantly at the cell surface where NTS 1 interacts with the neurotensin peptide. Moreover, the increased NTLI and NTS 1 receptor expression is associated with pemoline-induced SIB, and NTS 1 targeted drugs bi-directionally modulate pemolineinduced SIB. These results position the NTS 1 as a promising therapeutic target for the treatment of SIB.
These findings can be placed in a context of dopaminergic and glutamatergic signalling as these three systems are highly colocalised and relevant to pemoline-induced SIB. It has been demonstrated that neurotensin increases the release of dopamine after perfusion into the SN or VTA (Myers and Lee 1983) , apparently by attenuating dopamine and GABAmediated inhibition in the cell body region (Stuhrman and Roseberry 2015) . Neurotensin also exerts actions on presynaptic terminals of the dopaminergic neurons in the nucleus accumbens, to attenuate D 2 autoreceptor-mediated inhibition, thereby enhancing dopamine release during trains of electrical stimulation (Fawaz et al. 2009 ). Accordingly, it seems that the actions of the NTS 1 agonist PD149163 may enhance pemoline-induced release of dopamine, thereby accounting for the enhanced behavioural response in PD149163-treated rats. Conversely, the administration of the antagonist SR48692 would decrease pemoline-induced SIB by attenuating release of dopamine. Indeed, SR48692 inhibits neurotensin-stimulated [
3 H] dopamine release from striatal slices and mesencephalic cultures (Brouard et al. 1994) .
There is also evidence that neurotensin interactions with glutamatergic neurotransmission could contribute to the behavioural effects. Neurotensin 1004 (a) (b) Figure 3 Effects of the NTS 1 agonist, PD149163, on pemoline-induced SIB. Rats that were treated with pemoline plus PD149163 exhibited significantly larger areas of injured tissue and more time self-injuring than did the rats that were treated with pemoline plus vehicle. All values are expressed as group means ± SEM.
(a) (b) Figure 4 Effects of the NTS 1 antagonist, SR48692, on pemoline-induced SIB. Rats that were treated with pemoline plus SR48692 exhibited significantly smaller areas of injured tissue and less time self-injuring than did the rats that were treated with pemoline plus vehicle. All values are expressed as group means ± SEM.
increases glutamate release from corticostriatal neurons (Ferraro et al. 1995; Goedert, Pittaway, & Emson 1984) , and amplifies glutamate signalling through postsynaptic striatal NMDA receptors (Antonelli et al. 2004) . Accordingly, administration of PD149163 could enhance the actions of pemoline through striatal glutamate circuitry, resulting in increased expression of SIB. Indeed, the behavioural effects of PD149163 fit once again with the previous finding that pemoline-induced SIB is decreased by administration of the NMDA receptor antagonist MK-801 (King, Au, & Poland 1995; Muehlmann & Devine 2008) . Moreover, blocking the NTS 1 receptor blocks stimulant sensitisation (Panayi et al. 2005) , accounting for the diminished behavioural response in SR48692-treated animals after repeated pemoline treatment. This action concurs with our previous report that pemoline-induced SIB may arise from a sensitised response during repeated stimulant administration (Muehlmann & Devine 2008) .
There are additional brain systems through which neurotensin signalling could interact with pemoline to promote the expression of SIB (for review, refer to Boules et al. (2013) ). For example, neurotensin causes analgesia after intracisternal administration in mice (Nemeroff et al. 1979; Vincent, Mazella, & Kitabgi 1999) , which could diminish pain-related constraints on the expression of SIB in the pemoline-treated animals. This and other potential mediators of the behavioural effects of PD149163 and SR48692 could be further explored. However, in light of the foregoing evidence, we suggest that the interactions with dopamine and glutamate may be particularly important.
In summary, the results of our experiments reveal that increased neurotensin signalling enhances pemoline-induced SIB, and suggest that neurotensin may play a role in the aetiology and expression of SIB in children with autism and other neurodevelopmental disorders. Interestingly, it was recently reported that children with autism have significantly higher levels of serum neurotensin than do typically developing children (Angelidou et al. 2010; Tsilioni et al. 2014) . However, the potential relevance of this finding for central neurotensin functioning is not clear, and neither is the relevance for behavioural function in these children. Nevertheless, the finding that neurotensin plays a role in pemoline-induced SIB adds to a growing body of evidence implicating abnormalities in neurotensin signalling in autism and other neuropsychiatric disorders (Boules et al. 2014; Griebel and Holsboer 2012) . 
Sources of Funding
